A Clinical Study to Evaluate the Effect of Multiple Doses of Efavirenz on Single-Dose Pharmacokinetics of MK-7602 in Healthy Participants
Latest Information Update: 07 Mar 2025
Price :
$35 *
At a glance
- Drugs MK 7602 (Primary) ; Efavirenz
- Indications Malaria
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 28 Feb 2025 Status changed from not yet recruiting to recruiting.
- 06 Feb 2025 Planned initiation date changed from 10 Feb 2025 to 3 Mar 2025.
- 03 Feb 2025 New trial record